Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating how well elritercept works to improve anemia in adults with myelofibrosis MF who are already taking ruxolitinib. The study compares elritercept to a placebo and aims to learn if elritercept reduces tiredness, improves symptoms related to MF, helps participants be more active, and impacts the bone marrow and spleen. The safety of elritercept is also being assessed over a long period. This is a Phase 3, double-blind, randomized trial sponsored by Takeda. Participants will receive either elritercept or a matching placebo as a subcutaneous injection every 4 weeks for approximately 36 weeks during the double-blinded treatment period. Elritercept starts at a dose of 3.75 mgkg, with a possible increase to 5.0 mgkg from the third cycle based on response and safety. After this period, those on placebo may switch to elritercept during an extended open-label phase where dosing adjustments are also possible. During the study, participants will be monitored regularly with assessments including blood transfusion independence, fatigue levels, symptom scores, spleen size by imaging, and development of antibodies to the study drug. Researchers will track safety and overall survival for up to seven years. Participants can expect visits every 4 weeks during treatment, and the study includes long-term follow-up to evaluate treatment effects and safety.
Actively Recruiting
This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
This research aims to evaluate the effect of tozorakimab, given in addition to standard care, in adults hospitalized for viral lung infection who require supplemental oxygen. The study focuses on whether this treatment can prevent death or the need for invasive mechanical ventilation IMV or extracorporeal membrane oxygenation ECMO. It is a Phase III, randomized, double-blind, placebo-controlled trial assessing patients with hypoxaemia due to viral lung infection. Participants will be randomly assigned in equal numbers to one of two groups. One group will receive a single intravenous dose of tozorakimab on Day 1, while the other group will receive a matching placebo dose. Both groups will continue to receive standard care alongside the study treatment. The trial is designed to follow patients for up to 60 days to assess various clinical outcomes related to respiratory status and survival. During the study, participants will be monitored for progression to invasive ventilation or death up to 28 days as the primary outcome. Additional assessments include survival at 60 days, time spent outside the intensive care unit, days free from supplemental oxygen, and clinical progression scales. Safety evaluations include monitoring for anti-drug antibodies. The total participation time spans from treatment administration through clinical follow-up up to 60 days.
Actively Recruiting
This research investigates the effects of hypothermia versus normothermia on patients who have undergone extracorporeal cardiopulmonary resuscitation ECPR following out-of-hospital cardiac arrest OHCA. The trial aims to compare mortality risks, neurological outcomes, and adverse events between these two temperature management strategies. The study addresses uncertainties regarding the best temperature control after ECPR, which is a resuscitation method using ECMO to support heart and lung function during cardiac arrest. Participants receive either hypothermia treatment, where their body temperature is cooled to 33-34C using ECMO with a heat exchanger, or normothermia treatment, where the temperature is maintained at 36C. After reaching the target temperature, it is maintained for 24 hours, followed by a 24-hour rewarming period to 36-37.5C, which is then sustained until ECMO ends or for 24 hours post-rewarming. Additional treatments like sedation, muscle relaxants, antipyretics, and circulatory support may be used as needed. During the trial, participants are closely monitored for survival at discharge about 25 days, neurological function using cerebral performance categories, and adverse events during their intensive care stay approximately two weeks. Follow-up assessments occur at 30 days, 90 days, and one year after admission. The study tracks these outcomes to evaluate which temperature management approach might better support recovery after ECPR in OHCA patients.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of TARA-002, a biological preparation containing cells of Streptococcus pyogenes, in adults 18 years and older with high-grade non-muscle invasive bladder cancer NMIBC including carcinoma in situ CIS with or without TaT1. This Phase 2 open-label study aims to further assess TARA-002 at the recommended Phase 2 dose established in a prior dose-finding study. Participants include those who are BCG naive, BCG exposed but not recently treated, or BCG unresponsive. Participants will receive intravesical instillations of TARA-002 in a structured treatment schedule. The first period consists of 6 weekly doses. Those eligible for reinduction will receive another 6 weekly doses, while participants with a complete response after the first period will get 3 weekly maintenance doses. A third treatment period includes 3 weekly maintenance doses administered at months 6, 9, 12, 15, 18, and 24. Following treatment, participants enter a follow-up period lasting from month 27 to month 60. Throughout the study, participants will be monitored for tumor response, including high-grade complete response rates and duration, progression-free survival, cystectomy timing, and survival outcomes up to 60 months. Safety assessments include monitoring adverse events and biomarker changes in urine. Quality of life questionnaires will be administered up to 24 months. This comprehensive evaluation aims to understand TARA-002s effects and safety over time in this patient population.
Actively Recruiting
Researchers are conducting a phase 3b randomized, controlled trial to compare nadofaragene firadenovec versus observation in participants with intermediate risk non-muscle invasive bladder cancer IR NMIBC. The study aims to evaluate treatment effects on recurrence-free survival over a 24-month period. This trial is sponsored by Ferring Pharmaceuticals and focuses on participants who have undergone prior tumor resection and meet specific risk criteria according to established urological guidelines. Participants assigned to the nadofaragene firadenovec group will receive quarterly instillations of this vector-based gene therapy designed to boost the bodys interferon alfa-2b response for up to 24 months. Those in the observation group will be followed according to routine surveillance schedules recommended by the American Urological Association AUA and the Society of Urologic Oncology SUO, also on a quarterly basis for 24 months. Disease evaluations for treated participants will occur within two weeks prior to each treatment instillation. Throughout the study, participants will undergo regular disease evaluations and monitoring for adverse events up to 24 months. Researchers will measure recurrence-free survival at 12 and 24 months as primary and secondary outcomes. The trial design includes randomized allocation without masking, and participants will be followed during the treatment period and beyond for safety and efficacy assessments, with total participation lasting up to 24 months.